Antídotos e medicamentos utilizados para tratar intoxicações no Brasil: necessidades, disponibilidade e oportunidades
暂无分享,去创建一个
[1] J. Kalil,et al. Anti-Digoxin Fab Variants Generated by Phage Display , 2013, Molecular Biotechnology.
[2] D. Jacobsen,et al. A one-year observational study of all hospitalized acute poisonings in Oslo: complications, treatment and sequelae , 2012, Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine.
[3] R. Gair. Antidote program in British Columbia. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[4] V. Abbott,et al. Access in New Zealand to antidotes for accidental and intentional drug poisonings. , 2012, Journal of primary health care.
[5] M. Silva,et al. ECONOMIC EVALUATION OF POISON CENTERS: A SYSTEMATIC REVIEW , 2012, International Journal of Technology Assessment in Health Care.
[6] V. Cohen,et al. Antidotes for toxicological emergencies: a practical review. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[7] D. Spyker,et al. 2010 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 28th Annual Report , 2011, Clinical toxicology.
[8] T. Galvão,et al. Padronização das informações toxicológicas no Brasil , 2011 .
[9] Edgar Hernández-Leiva. Epidemiología del síndrome coronario agudo y la insuficiencia cardiaca en Latinoamérica , 2011 .
[10] James A. Swenberg,et al. Toxicology and Epidemiology: Improving the Science with a Framework for Combining Toxicological and Epidemiological Evidence to Establish Causal Inference , 2011, Toxicological sciences : an official journal of the Society of Toxicology.
[11] N. Buckley,et al. Oximes for acute organophosphate pesticide poisoning. , 2011, The Cochrane database of systematic reviews.
[12] Carlos Alberto Silva,et al. Impact of a poison control center on the length of hospital stay of poisoned patients: retrospective cohort. , 2011, Sao Paulo medical journal = Revista paulista de medicina.
[13] G. C. Rodgers,et al. Antidotes and Treatments for Chemical Warfare/Terrorism Agents: An Evidence‐Based Review , 2010, Clinical pharmacology and therapeutics.
[14] J. Feussner,et al. Reassessing the efficacy of digitalis: from routine treatment to evidence-based medicine. , 2010, The American journal of the medical sciences.
[15] K. Wong,et al. Availability of antidotes for the treatment of acute poisoning in Queensland public hospitals. , 2010, The Australian journal of rural health.
[16] Silas W Smith. Drugs and pharmaceuticals: management of intoxication and antidotes , 2010, EXS.
[17] C. Smollin. Toxicology: pearls and pitfalls in the use of antidotes. , 2010, Emergency medicine clinics of North America.
[18] R. Wise,et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. , 2009, Annals of emergency medicine.
[19] K. Kehe,et al. Development of antidotes: problems and strategies. , 2007, Toxicology.
[20] C. Steffen. The dilemma of approving antidotes. , 2007, Toxicology.
[21] J. Brubacher,et al. Adequacy of antidote stocking in British Columbia hospitals: the 2005 Antidote Stocking Study. , 2006, CJEM.
[22] D. Roberts,et al. Antidotes for acute cardenolide (cardiac glycoside) poisoning. , 2006, The Cochrane database of systematic reviews.
[23] P. Hauptman,et al. Digoxin use and digoxin toxicity in the post-DIG trial era. , 2006, Journal of cardiac failure.
[24] C. Morillo,et al. Congestive heart failure in Latin America: the next epidemic. , 2004, American heart journal.
[25] J. Bussières,et al. Availability of antidotes in Quebec hospitals before and after dissemination of guidelines. , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[26] D. Bouros,et al. Availability of antidotes in hospital pharmacies in Greece. , 2001, Veterinary and human toxicology.
[27] A. Woolf,et al. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. , 2000, Annals of emergency medicine.
[28] S. Walton,et al. Analysis of the Use of Digoxin Immune Fab for the Treatment of Non-Life-Threatening Digoxin Toxicity , 2000, Journal of cardiovascular pharmacology and therapeutics.
[29] S. Lowenstein,et al. Insufficient stocking of poisoning antidotes in hospital pharmacies. , 1996, JAMA.
[30] C. Gadelha. The production and development of vaccines in Brazil , 1996 .
[31] T. Wenger,et al. Cost-effectiveness analysis of the use of digoxin immune Fab (ovine) for treatment of digoxin toxicity. , 1991, The American journal of cardiology.
[32] Daniel Marques Mota,et al. Perfil da mortalidade por intoxicação com medicamentos no Brasil, 1996-2005: retrato de uma década , 2012 .
[33] Amy F Wolkin,et al. Using poison center data for national public health surveillance for chemical and poison exposure and associated illness. , 2012, Annals of emergency medicine.
[34] J. Brubacher,et al. Antidote stocking in British Columbia hospitals. , 2003, CJEM.
[35] Nara Azevedo,et al. Inovao em vacinas no Brasil: experincia recente e constrangimentos estruturais , 2003 .
[36] J. Bussières,et al. Antidote availability in Quebec hospital pharmacies: impact of N-acetylcysteine and naloxone consumption. , 2000, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.
[37] K. Luomanmäki,et al. [Calcium channel blocker poisoning]. , 1993, Duodecim; laaketieteellinen aikakauskirja.